UMIN-CTR History

Name：　　UMIN ID：


Unique ID issued by UMIN UMIN000021480
Receipt number R000024753
Scientific Title Phase I study of pre-operative combination therapy with Mogamulizumab (anti-CCR4) and Nivolumab (anti-PD-1) against solid cancer patients
Date of disclosure of the study information 2016/03/15
Last modified on 2021/04/06 09:17:20

No. Disposal Last modified on Item of update
1 Insert 2016/03/15 18:59:09
2 Update 2016/10/03 19:37:54 Primary outcomes
Primary outcomes
Key secondary outcomes
3 Update 2016/10/03 19:38:52 Basic design
Key inclusion criteria
Key inclusion criteria
4 Update 2016/10/03 19:42:17 Name of primary person or sponsor
Institute
Department
Organization
Organization
Category of Funding Organization
5 Update 2018/12/13 16:47:02 Organization
Organization
Organization
Division
Category of Funding Organization
Name of secondary funder(s)
Name of secondary funder(s)
6 Update 2019/01/04 18:00:33 Condition
Condition
Classification by specialty
Narrative objectives1
7 Update 2019/01/04 18:03:50 Key inclusion criteria
Key inclusion criteria
Key exclusion criteria
Key exclusion criteria
8 Update 2019/03/19 12:20:50 Basic design
Control
No. of arms
Interventions/Control_1
Interventions/Control_1
Interventions/Control_2
Interventions/Control_2
Interventions/Control_3
Interventions/Control_3
9 Update 2019/03/19 12:24:40 1st name of lead principal investigator
Last name of lead principal investigator
1st name of lead principal investigator
Last name of lead principal investigator
Zip code

Last name of contact person

Last name of contact person
Zip code
Organization
Organization
Address
Address
Tel
Email
10 Update 2019/03/19 12:27:57 Date of IRB
Last follow-up date
11 Update 2019/06/20 11:07:17 Key exclusion criteria
Key exclusion criteria
12 Update 2019/06/20 11:12:50 Address
Address
Address
Address
Organization
Address
Address
13 Update 2019/09/17 09:30:37 Address
Address
Address
Address
Name of secondary funder(s)
14 Update 2020/03/05 11:46:15 Recruitment status
15 Update 2020/03/05 11:47:32 Number of participants that the trial has enrolled
16 Update 2020/03/31 16:15:59 Last follow-up date
17 Update 2021/04/06 09:17:20 Recruitment status